Unravelling the Lesser Known Facets of Angiotensin II Type 1 Receptor

Chaudhary, Mayank; Chaudhary, Shashi

doi:10.1007/s11906-017-0699-0

Cited by 8 publications

(5 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BP can be altered by an imbalance between relaxation and contraction processes. In this sense, TGF-β1 has been also reported to regulate the expression of angiotensin II type1 receptor (AT 1 ), the receptor by which angiotensin II acts as vasoconstrictor (Chaudhary and Chaudhary, 2017).…”

Section: Introductionmentioning

confidence: 99%

Environmental pollutant hexachlorobenzene induces hypertension in a rat model

et al. 2018

View full text Add to dashboard Cite

Hexachlorobenzene (HCB) is a dioxin-like environmental pollutant, widely distributed in the environment. New research links exposure to high levels of persistent organic environmental toxicants to cardiovascular disease, however little is known about the effect of HCB on vascular function and on blood pressure. The purpose of the present study was to evaluate biochemical and cardiovascular changes resulting from subchronic HCB exposure. Adult female Sprague-Dawley rats were treated with vehicle or HCB (5 or 500 mg/kg b.w) for 45 days. Systolic blood pressure (BP), recorded by tail cuff plethysmography, was significantly increased at 35, 40 and 45 days of 500 mg/kg HCB-treatment. HCB (500 mg/kg) increased arterial thickness, while both 5 and 500 mg/kg HCB decreased proliferating cell nuclear antigen (PCNA) protein levels and cellular nuclei in abdominal aortas indicating a hypertrophic process. Also, aortas from both groups of HCB-treated rats presented higher sensitivity to noradrenalin (NA) and a significant decrease in maximum contractile response. Arteries from 500 mg/kg HCB-treated rats showed a significant increase in the levels of transforming growth factor-β1 (TGF-β1) mRNA and angiotensin II type1 receptor (AT), and a significant decrease in estrogen receptor alpha (ERα), endothelial nitric oxidide synthase (eNOS) protein expression and deiodinase II (DII) mRNA levels. In conclusion, we have demonstrated for the first time that subchronic HCB administration significantly increases BP and alters associated cardiovascular parameters in rats. In addition, HCB alters the expression of key vascular tissue molecules involved in BP regulation, such as TGF-β1, AT1, ERα, eNOS and DII.

show abstract

Section: Introductionmentioning

confidence: 99%

Environmental pollutant hexachlorobenzene induces hypertension in a rat model

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Another important player in the renin-angiotensin system AT1R is, which exerted a number of angiotensin II effects such as vasoconstriction, angiogenesis, matrix synthesis, and aldosterone synthesis. AT1R is localized mostly in the adult cardiovascular tissue, it is present in the brain, kidneys, and adrenal glands ( Chaudhary and Chaudhary, 2017 ). Moreover, this receptor participated in angiotensin II-induced oxidant stress, and NF-κB activation with the enhanced expression of IL-6, VCAM-1, and MCP-1 ( MacKenzie, 2011 ).…”

Section: Discussionmentioning

confidence: 99%

Allele С (rs5186) of at1r is associated with the severity of COVID-19 in the Ukrainian population

Измайлова

Shlykova

Vatsenko

et al. 2022

Infection, Genetics and Evolution

View full text Add to dashboard Cite

Introduction The severity of SARS-CoV-2 induced coronavirus disease 19 (COVID-19) depends on the presence of risk factors and the hosts' gene variability. There are preliminary results that gene polymorphisms of the renin-angiotensin system can influence the susceptibility to and mortality from COVID-19. Angiotensin II type 1 receptor (AT1R) might be a gene candidate that exerts such influence. The aim of this study was to elaborate on the association between A1166C at1r polymorphic variants and the susceptibility to and severity of COVID-19 in the Ukrainian population. Methods The study population consisted of the Ukrainian population (Poltava region) with COVID-19, divided into three clinical groups in accordance with oxygen requirement: patients without oxygen therapy ( n = 110), with non-invasive ( n = 136) and invasive ( n = 36) oxygen therapy. The A1166C polymorphism of the at1r was determined by polymerase chain reaction with subsequent restrictase analysis. In an attempt to better explain the role of the A1166C at1r polymorphism we compared its association with COVID-19, essential hypertension ( n = 79), renoparenchimal hypertension ( n = 30) and dyscirculatory encephalopathy ( n = 112). The data for this comparison were obtained by meta-analysis. Results We observed significant differences in the frequency of AA, AC and CC genotypes in the groups of COVID-19 patients with non-invasive and invasive oxygen therapy in comparison with control subjects as well as in the frequency of combined AC + CC genotype between the groups of COVID-19 patients with any types of oxygen therapy and patients without oxygen therapy. The frequency of the 1166C allele was higher in COVID-19 patients with invasive oxygen therapy (OR = 2.06; CI (1.20–3.53); p = 0.013). We obtained important results indicating that there were no differences between the frequency of at1r polymorphisms in patients with cardiovascular disease and severe COVID-19 with invasive oxygen therapy as well as those who died due to COVID-19. Conclusion Our study indicated the presence of an association between the A1166C at1r polymorphisms and the severity of COVID-19 in the Ukrainian population. It seems that in carriers of 1166C at1r , the severity of COVID-19 and oxygen dependency is higher as compared to the A allele carriers, possibly, due to cardiovascular disorders.

show abstract

“…AT 1 R is mainly expressed in various tissues of the cardiovascular system including kidney, heart, endothelium, and vascular smooth muscle. AT 1 R promotes various intracellular signaling pathways resulting in hypertension, endothelial dysfunction, vascular remodeling, and end organ damage [44,45]. It is the last target of the therapeutic vaccines designed so far.…”

Section: Angiotensin II Type 1 Receptor (At 1 R)mentioning

confidence: 99%

Vaccines against components of the renin–angiotensin system

et al. 2020

View full text Add to dashboard Cite

Even though effective drugs for treating hypertension are available, a great percentage of patients have inadequate control of their blood pressure. Unwanted side effects and inappropriate oral drug adherence are important factors that contribute to the global problem of uncontrolled hypertension. Vaccination could provide a revolutionary therapy with long-lasting effects, increasing patient compliance and therefore better control of high blood pressure. Nowadays, current immunization approaches against hypertension target renin, angiotensin I, angiotensin II, and angiotensin II type 1 receptor, key elements of the renin-angiotensin system. This article reviews the different vaccination attempts with proteins and peptides against the different molecules of the renin-angiotensin system in the last two decades, safety issues, and other novel prospects biomarkers in hypertension, and summarizes the potential of this immunomodulatory approach in clinical practice.

show abstract

Unravelling the Lesser Known Facets of Angiotensin II Type 1 Receptor

Cited by 8 publications

References 88 publications

Environmental pollutant hexachlorobenzene induces hypertension in a rat model

Environmental pollutant hexachlorobenzene induces hypertension in a rat model

Allele С (rs5186) of at1r is associated with the severity of COVID-19 in the Ukrainian population

Vaccines against components of the renin–angiotensin system

Contact Info

Product

Resources

About